Figure 1. Evolution from autologous to off-the-shelf cell therapy. Comparison of autologous and allogeneic cell therapy manufacturing workflows. Unlike patient-specific manufacturing, iPSC-derived allogeneic therapies leverage Master Cell Banks (MCBs), standardized manufacturing processes, and large-scale production to enable scalable, off-the-shelf regenerative medicine. Executive Summary Key Takeaways Induced pluripotent stem cells (iPSCs) have evolved from a stem cell tech